Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 1
2007 1
2008 1
2009 2
2010 1
2012 3
2013 3
2014 10
2015 8
2016 6
2017 8
2018 16
2019 11
2020 12
2021 10
2022 11
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 37653589

101 results

Results by year

Filters applied: . Clear all
Page 1
Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial.
Zhao X, Chen Z, Zhang X, Zhu X, Zhang W, Qiu L, Wang C, Huang M, Zhang Z, Li W, Yang L, Guo W. Zhao X, et al. Cancer Biol Med. 2023 Aug 31;20(9):682-8. doi: 10.20892/j.issn.2095-3941.2023.0112. Cancer Biol Med. 2023. PMID: 37653589 Free PMC article. Clinical Trial.
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K. Hirata K, et al. BMC Cancer. 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1. BMC Cancer. 2020. PMID: 32532230 Free PMC article.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
Lorenzen S, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Knorrenschild JR, Illerhaus G, Dechow T, Moehler M, Moulin JC, Pink D, Stahl M, Schaaf M, Goetze TO, Al-Batran SE. Lorenzen S, et al. BMC Cancer. 2023 Jun 19;23(1):561. doi: 10.1186/s12885-023-11004-z. BMC Cancer. 2023. PMID: 37337155 Free PMC article. Clinical Trial.
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Shitara K, et al. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. doi: 10.1016/S2468-1253(16)30219-9. Epub 2017 Jan 19. Lancet Gastroenterol Hepatol. 2017. PMID: 28404157 Clinical Trial.
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S, Taniguchi H, Nishikawa K, Imamura H, Fujita J, Takeno A, Matsuyama J, Kimura Y, Kawada J, Hirao M, Hirota M, Fujitani K, Kurokawa Y, Sakai D, Kawakami H, Shimokawa T, Satoh T. Tamura S, et al. Int J Clin Oncol. 2020 Dec;25(12):2035-2043. doi: 10.1007/s10147-020-01768-w. Epub 2020 Sep 14. Int J Clin Oncol. 2020. PMID: 32926227 Free PMC article. Clinical Trial.
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Xu RH, et al. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7. Epub 2021 Oct 7. Lancet Gastroenterol Hepatol. 2021. PMID: 34626550 Clinical Trial.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Wilke H, et al. Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17. Lancet Oncol. 2014. PMID: 25240821 Clinical Trial.
101 results